Icon (ICLR) Upgraded at BidaskClub

BidaskClub upgraded shares of Icon (NASDAQ:ICLR) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Other analysts have also issued research reports about the company. Zacks Investment Research raised Icon from a hold rating to a buy rating and set a $163.00 target price for the company in a report on Thursday, August 9th. Mizuho set a $146.00 price objective on Icon and gave the stock a hold rating in a report on Monday, August 6th. Evercore ISI raised Icon from an in-line rating to an outperform rating in a report on Friday, October 26th. Robert W. Baird lifted their price objective on Icon from $154.00 to $157.00 and gave the stock an outperform rating in a report on Tuesday, September 11th. Finally, KeyCorp lifted their price objective on Icon from $152.00 to $157.00 and gave the stock an overweight rating in a report on Tuesday, September 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $148.00.

Icon stock opened at $147.17 on Friday. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 2.08 and a beta of 0.55. Icon has a 12 month low of $101.22 and a 12 month high of $155.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, hitting the Zacks’ consensus estimate of $1.54. The business had revenue of $655.02 million during the quarter, compared to analyst estimates of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. Equities research analysts forecast that Icon will post 6.08 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale grew its holdings in shares of Icon by 119.7% in the third quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock worth $113,000 after acquiring an additional 419 shares during the period. Fort L.P. bought a new stake in shares of Icon in the second quarter worth $121,000. Capital Advisors Ltd. LLC bought a new stake in shares of Icon in the third quarter worth $121,000. Csenge Advisory Group bought a new stake in shares of Icon in the third quarter worth $150,000. Finally, Prudential Financial Inc. bought a new stake in shares of Icon in the third quarter worth $200,000. 86.54% of the stock is owned by institutional investors.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit